主要目的：评价RC19D2细胞注射液治疗CD19阳性的复发或难治性弥漫大B细胞淋巴瘤患者的安全性和耐受性；确定Ⅱ期临床试验的推荐给药剂量（RP2D）。次要目的：评价RC19D2细胞注射液治疗CD19阳性的复发或难治性弥漫大B细胞淋巴瘤的初步疗效；评价RC19D2细胞注射液在CD19阳性的复发或难治性弥漫大B细胞淋巴瘤患者中的细胞代谢动力学；评价RC19D2细胞注射液在CD19阳性的复发或难治性弥漫大B细胞淋巴瘤患者中的药效动力学；评价RC19D2细胞注射液的免疫原性。

开始日期2023-10-31

申办/合作机构

北京永泰瑞科生物科技有限公司

NCT06047197 / Recruiting临床1期

Phase I Clinical Trial of Dinorencel Injection (or RC19D2 Cell Injection) in the Treatment of CD19-positive Relapsed or Refractory Diffuse Large B-cell Lymphoma

This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma

开始日期2023-09-05

申办/合作机构

北京永泰瑞科生物科技有限公司

NCT03720457 / Unknown status临床1期

A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma

To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.

开始日期2018-11-13

申办/合作机构

上海恒润达生生物科技股份有限公司初创企业

[+1]

100 项与 CD19阳性弥漫性大B细胞淋巴瘤相关的临床结果

登录后查看更多信息

100 项与 CD19阳性弥漫性大B细胞淋巴瘤相关的转化医学

登录后查看更多信息

0 项与 CD19阳性弥漫性大B细胞淋巴瘤相关的专利（医药）

登录后查看更多信息

项与 CD19阳性弥漫性大B细胞淋巴瘤相关的文献（医药）

2023-04-01·Asian Journal of Surgery

CD5-positive primary diffuse large B-cell lymphoma of the breast: A case report

Letter

作者: Ye, Miao ; Zhuang, Yongwei ; Song, Chengjun ; Zeng, Yuxiao

2020-05-01·Journal of International Medical Research4区 · 医学

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?

4区 · 医学

ReviewOA

作者: Shen, Jianzhen ; Liu, Tingbo ; Awal Issah, M. ; Liu, Yanquan ; Zhou, Huarong ; Fu, Haiying

Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma (NHL) and is highly invasive, with a poor prognosis. The main clinical treatment for DLBCL involves chemotherapy or a combination of chemotherapy and targeted drugs. CD56 expression is considered as an indicator of poor prognosis in patients with acute myeloid leukemia and anaplastic large cell lymphoma; however, its role in DLBCL remains unclear. We report on a patient with CD56-positive DLBCL/leukemia with BCL6/ MYC double-hit, and DDX3X, LRP1B, SIN3A, and GNA13 gene mutations (stage IVA, prognostic index aaIPI = 2 points). The patient was treated with cyclophosphamide and prednisone pre-chemotherapy plus R-Hyper-CVAD AB and DA-EPOCH regimens. Lumbar puncture combined with intrathecal injection was performed to prevent central nervous system infiltration during hospitalization, and complete remission was confirmed. We also reviewed the literature to clarify the relevance of the unique clinical features associated with this case.

2019-12-08·Zhonghua bing li xue za zhi = Chinese journal of pathology

[CD3-positive diffuse large B-cell lymphoma of fusiform cells in colon].

Article

作者: Zhou, X G ; Xie, J L ; Ma, D Y ; Zhang, Y L ; Zheng, Y Y

弥漫性大B细胞淋巴瘤是一类由大B细胞样细胞构成的肿瘤，是目前最常见的非霍奇金淋巴瘤；形态学上以圆形、类圆形细胞构成为主，而梭形细胞是一种比较罕见的类型。该文中讨论的病例是发生在结肠以梭形细胞为主的弥漫性大B细胞淋巴瘤，免疫表型同时表达B细胞抗体和T细胞抗体CD3；基因重排检测出B细胞、T细胞均呈单克隆表达。给临床病理诊断带来一定的困难，容易造成误诊，需提高警惕。.